Loading
Latest filing published 05 Nov 2024 for BioRestorative Therapies, Inc., €1,627.
Across 17 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Dale Broadrick, listed as chief executive, appears in our data through filings on BioRestorative Therapies, Inc. shares, published by SEC (Form 4). In total, 110 filings cover trades dated from 26 February 2019 to 28 October 2024.
The open-market side counts 106 purchases for €3.0M alongside 4 sales for €8,949. Taken together, the purchases exceed the sales by €3.0M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2024 to date brings 4 purchases and 1 sale.
A typical purchase (the median) is worth €4,962. Clusters matter here: 39 out of 106 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.
The newest entry dates from 5 November 2024: an open-market sale of €1,627, in BioRestorative Therapies, Inc. The last purchase on record was published on 12 February 2024, which is 984 days ago. Filings reach the SEC (Form 4) feed a median of 7 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 26 declarations